We examined the SUCLG2 expression levels in 12 glioma tissue samples (four each from Grades II, III, and IV) and four samples of injured brain tissues using western blot analysis, real-time quantitative polymerase chain reaction (RT-qPCR), and immunohistochemistry (IHC). This evidence concerns the gene SUCLG2 and central nervous system cancer.